DOCSLIB.ORG

Sunday, October 18, 2015 • Registration Opens (8:00Am-6:00Pm)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sunday, October 18, 2015 • Registration Opens (8:00Am-6:00Pm) Wednesday, October 21, 2015 Registration (7:00am‐5:00pm) Exhibit Hall/Auction Open (7:00am‐5:00pm) Continental Breakfast (7:00am‐8:30am) Sunday, October 18, 2015 JAT/OUP Breakfast Meeting (7:00am‐8:00am) Opening Ceremony (Plenary) (8:00am‐9:00am) Registration Opens (8:00am‐6:00pm) Scientific Session #1 (9:00am‐10:00am) NSC‐ADID Meeting (8:00am‐12:00pm) Refreshment Break (10:00am‐10:30am) NLCP Inspector Training (2:00pm‐6:00pm) Scientific Session #2 (10:30am‐12:00pm) YFT Symposium (5:00pm‐9:00pm) Lunch with Exhibitors (12:00pm‐1:30pm) Dinner On Your Own Poster Session #1 in Exh. Hall (12:00pm‐1:30pm) TBD‐Immunalysis hosted Sun. Eve. Reception Scientific Session #3 (1:30pm‐3:00pm) (6:00pm‐9:00pm) Refreshment Break (3:00pm‐3:30pm) Scientific Session #4 (3:30pm‐5:00pm) Monday, October 19, 2015 Explore the Georgia Aquarium (6:00pm‐10:00pm) TBD‐Nite Owl “XV” Reception, hosted by Continental Breakfast (7:00am‐8:30am) Cerilliant (10:00pm‐mid) Registration (7:00am‐6:00pm) ABFT Exam Committee (8:00am‐5:00pm) Thursday, October 22, 2015 Student Enrichment Progr. (8:00am‐5:00pm) SOFT Workshops (8:00am‐5:30pm) Registration (7:00am‐5:00pm) ABFT Lab. Accred. Comm. (8:00am‐5:00pm) Karla Moore Fun Run/Walk (6:30am‐8:00am) Lunch On Your Own Continental Breakfast (7:00am‐8:30am) ABFT Exec. Comm. Meet (12:00pm‐5:00pm) AAFS Steering Committee (7:00am‐9:00am) SOFT‐AAFS Drugs & Driving (5:30pm‐7:00pm) Exhibit Hall Open (7:00am‐3:30pm) Dinner On Your Own Silent Auction Open (7:00am – 1:30pm) Exhibitor Feedback Meeting (8:00am‐9:30am) Tuesday, October 20, 2015 SWGTOX update (8:00am‐8:30am) Scientific Session #5 (8:30am‐10:00am) Continental Breakfast (7:00am‐8:30am) Refreshment Break (10:00am‐10:30am) Registration (7:00am‐6:00pm) Scientific Session #6 (10:30am‐12:00pm) SOFT Board Meeting (7:00am‐12:00pm) Lunch with Exhibitors (12:00pm‐1:30pm) SOFT Workshops (8:00am‐5:30pm) Poster Session #2 in Exh. Hall (12:00pm‐1:30pm) ABFT Exam (8:00am‐12:00pm) DFC Committee (12:00pm‐1:00pm) ABFT Lab. Accred. Comm. (8:00am‐12:00pm) Scientific Session #7 (1:30pm‐3:00pm) ABFT Board Meeting (12:00pm‐5:00pm) Refreshment Break (3:00pm‐3:30pm) Welcome Recep.w/Exhibits (6:30pm‐9:00pm) Silent Auction Pay/Pick‐Up (3:00pm‐3:30pm) Sunshine/Rieders Auction (6:30pm‐8:00pm) SOFT Business Meeting (3:30pm‐5:00pm) Professional Develop. Fair (6:30pm‐8:00pm) ABFT Certificate Reception (5:00pm‐6:00pm) Elmer Gordon Forum (8:00pm‐9:30pm) Happy Hour (5:00pm‐6:00pm) TBD‐SOFToberfest Reception, hosted by President’s Reception & Dance (6:00pm‐10:00pm) Thermo Fisher Scientific (9:30pm‐mid) Friday, October 23, 2015 EXHIBITS OPEN Continental Breakfast (7:00am‐8:30am) Tuesday – 6:30pm‐9:00pm Scientific Session #8 (8:00am‐10:00am) Wednesday – 7:00am‐5:00pm Refreshment Break (10:00am‐10:30am) Thursday – 7:30am‐3:30pm Scientific Session #9 (10:30am‐12:00pm) Closing Ceremony (12:00pm‐12:30pm) Update – Sept. 17, 2014 Lunch On Your Own S01 Analysis of Acetyl Fentanyl in Postmortem Blood and Urine Specimens by Gas Chromatography-Mass Spectrometry Marissa J. Finkelstein*1, Chris W. Chronister1, Christina Stanley2, Laurie Ogilvie2 and Bruce A. Goldberger1; 1University of Florida Health Pathology Laboratories – Forensic Toxicology Laboratory, Gainesville, FL, 2Rhode Island Office of State Medical Examiners, Providence, RI Background/Introduction: Acetyl fentanyl was first synthesized as an analog of fentanyl in 1960. Its recreational use peaked in 2013. Since the spring of 2013, at least 31cases have been reported in North Carolina, Florida, Rhode Island, West Virginia, Louisiana, and Maryland. Acetyl fentanyl is a μ-opioid agonist, and its pharmacological effects include altered mood, euphoria, respiratory depression, and central nervous system depression. Acetyl fentanyl is used as a substitute for heroin because of its similar pharmacological effects. Due to its structural similarity to fentanyl, acetyl fentanyl exhibits significant cross-reactivity to fentanyl enzyme-linked immunosorbent assays (ELISA). Objective: The objective of this study was to quantitate acetyl fentanyl in postmortem blood and urine specimens, as well as to investigate the decedent demographic characteristics in order to determine potential factors indicative of acetyl fentanyl use with regards to age, sex, race, and drug use. Method: Solid-phase extraction (SPEware CEREX ® Trace-B) was used to isolate acetyl fentanyl from the biological matrices. The samples were subsequently analyzed by gas chromatography mass spectrometry (GC-MS) in selected ion monitoring mode for quantitative analysis. This method was developed and validated according to standards established by the Scientific Working Group for Forensic Toxicology (SWGTOX). The method exhibited a linear calibration range from 2.5-50 ng/mL. The lower limit of quantitation was determined as the lowest non-zero calibrator, 2.5 ng/mL. The limit of detection was 0.5 ng/mL and 0.75 ng/mL in blood and urine, respectively. The method was used to quantitate acetyl fentanyl in 19 cases obtained from the Rhode Island Office of State Medical Examiners and the University of Florida (UF) Health Pathology Laboratories – Forensic Toxicology Laboratory. Additionally, all cases were subjected to comprehensive postmortem drug screening. Race was categorized as Caucasian, African American, and other. Age at death was divided into six cohorts: < 20, 21-30, 31-40, 41-50, 51-60, and > 61 years of age. Additional toxicology findings were categorized by drug class: opiates/opioids, benzodiazepines, cocaine, cannabinoids, amphetamines, and ethanol. The circumstances surrounding the death of each decedent and the route of administration of acetyl fentanyl were also investigated. Result: Since 2013, the Rhode Island Office of State Medical Examiners and the UF Health Pathology Laboratories – Forensic Toxicology Laboratory have received 19 cases involving the use of the designer drug acetyl fentanyl. The acetyl fentanyl blood concentrations ranged from 1.2-945 ng/mL. Acetyl fentanyl use was found to be most prevalent among males and individuals aged 21-30 years. Caucasians (18) exhibited the highest rate of acetyl fentanyl use, and additional analytes, apart from acetyl fentanyl, were present in all of the decedents. The additional toxicology findings were as follows: benzodiazepines (6), cocaine (9), opiates (13), amphetamines (1), cannabinoids (6), and ethanol (8). The analysis of circumstances of death indicated eight cases with a prior history of drug abuse, seven decedents with intravenous drug abuse or paraphernalia, and five cases indicated needle punctures. Conclusion: SPE followed by GC-MS analysis was determined to be a sensitive and specific method for the quantitation of acetyl fentanyl in postmortem blood and urine. A majority of cases investigated indicated concentrations significantly higher than the typical lethal concentration of fentanyl. It was found that males from 21- 40 years old (52%), followed by females from 51-60 years old (15%), showed the highest acetyl fentanyl prevalence for the analyzed cases. All of the decedents were Caucasian, except for one 27 year old African American female. In all cases, additional drugs were detected on the comprehensive drug screen, and a majority of the cases had a prior history of drug abuse. Keywords: Acetyl Fentanyl, GC-MS, Postmortem Toxicology, Method Validation S02 Direct Quantification of Cannabinoids, Metabolites and Glucuronides in Blood by Disposable Pipette Extraction and Liquid Chromatography-Tandem Mass Spectrometry Matthew N. Newmeyer*1,2, Karl B. Scheidweiler1, Allan J. Barnes1 and Marilyn A. Huestis1; 1Chemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, 2Program in Toxicology, University of Maryland Baltimore, Baltimore, MD Background/Introduction: Cannabis is the most commonly abused drug worldwide. The primary active ingredient, Δ9-tetrahydrocannabinol (THC), is metabolized to 11-hydroxy-THC (11-OH-THC) and 11-nor-9-carboxy-THC (THCCOOH), with subsequent phase II glucuronidation. Cannabinoids are lipophilic and undergo prolonged excretion following chronic frequent intake, making identification of recent cannabis intake difficult. We previously found THC-glucuronide and minor plant cannabinoids, cannabidiol (CBD) and cannabinol (CBN), in blood for up to 0.6, 0.5, and 2.1 h, respectively, after initiation of cannabis smoking, suggesting applicability for identifying recent intake. Similarly, cannabigerol (CBG), Δ9-tetrahydrocannabivarin (THCV), and the metabolite 11-nor-9-carboxy-THCV (THCVCOOH) might provide additional markers of recent intake. Sensitive and comprehensive methods for quantification of multiple cannabinoids in blood are needed to improve interpretation of results. Disposable pipette extraction (DPX) tips offer a novel, automatable technique for extracting cannabinoids from blood. Objective: To develop a comprehensive, sensitive blood cannabinoid quantification method for THC, 11-OH-THC, THCCOOH, CBD, CBN, CBG, THCV, THCVCOOH, THC-glucuronide and THCCOOH-glucuronide. Method: 200 µL blood was fortified with d3-THC, d3-11-OH-THC, d9-THCCOOH, d3-CBD, d3-CBN, and d3- THCCOOH-glucuronide internal standards. Proteins were precipitated with 500 µL acetonitrile followed by centrifugation at 15,000g, 4°C for 5 min. 550 µL supernatant was transferred to a clean microcentrifuge tube containing 200 µL 5% aqueous formic acid. The solution was aspirated 4 times through WAX-S tips (DPX Labs, Columbia, SC, 1 mL tip containing 20 mg resin and 40 mg salt). 90 µL upper, organic layer was transferred to a clean microcentrifuge tube containing 210 µL mobile phase A before centrifugation at 15,000g, 4°C for 5 min. The resulting supernatant was transferred to an autosampler vial. Gradient elution was performed with 10 mM ammonium acetate in water (A) and 15% methanol in acetonitrile (B) at 0.5 mL/min on a Kinetex C18 column (Phenomenex Inc, Torrance CA, 2.1 mm x 50 mm; 2.6 um) with 33 µL injection volume.
Load more

Recommended publications
  • Tyler's Herbs of Choice: the Therapeutic Use of Phytomedicinals Category
    Tyler’s Herbs of Choice The Therapeutic Use of Phytomedicinals Third Edition © 2009 by Taylor & Francis Group, LLC Tyler’s Herbs of Choice The Therapeutic Use of Phytomedicinals Third Edition Dennis V.C. Awang Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business © 2009 by Taylor & Francis Group, LLC CRC Press Taylor & Francis Group 6000 Broken Sound Parkway NW, Suite 300 Boca Raton, FL 33487-2742 © 2009 by Taylor & Francis Group, LLC CRC Press is an imprint of Taylor & Francis Group, an Informa business No claim to original U.S. Government works Printed in the United States of America on acid-free paper 10 9 8 7 6 5 4 3 2 1 International Standard Book Number-13: 978-0-7890-2809-9 (Hardcover) This book contains information obtained from authentic and highly regarded sources. Reasonable efforts have been made to publish reliable data and information, but the author and publisher can- not assume responsibility for the validity of all materials or the consequences of their use. The authors and publishers have attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint. Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers.
    [Show full text]
  • Substance Abuse: the Pharmacy Educator’S Role in Prevention and Recovery
    Substance Abuse: The Pharmacy Educator’s Role in Prevention and Recovery Curricular Guidelines for Pharmacy: Substance Abuse and Addictive Disease i Curricular Guidelines for Pharmacy: Substance Abuse and Addictive Disease1,2 BACKGROUND OF THE CURRICULUM DEVELOPMENT PROJECT In 1988, the AACP Special Interest Group (SIG) on Pharmacy Student and Faculty Impairment (renamed Substance Abuse Education and Assistance) undertook the development of curricular guidelines for colleges/schools of pharmacy to facilitate the growth of educational opportunities for student pharmacists. These Curricular Guidelines for Pharmacy Education: Substance Abuse and Addictive Disease were published in 1991 (AJPE. 55:311-16. Winter 1991.) One of the charges of the Special Committee on Substance Abuse and Pharmacy Education was to review and revise the 1991 curricular guidelines. Overall, the didactic and experiential components in the suggested curriculum should prepare the student pharmacist to competently problem-solve issues concerning alcohol and other drug abuse and addictive diseases affecting patients, families, colleagues, themselves, and society. The guidelines provide ten educational goals, while describing four major content areas including: psychosocial aspects of alcohol and other drug use; pharmacology and toxicology of abused substances; identification, intervention, and treatment of people with addictive diseases; and legal/ethical issues. The required curriculum suggested by these guidelines addresses the 1 These guidelines were revised by the AACP Special Committee on Substance Abuse and Pharmacy Education. Members drafting the revised guidelines were Edward M. DeSimone (Creighton University), Julie C. Kissack (Harding University), David M. Scott (North Dakota State University), and Brandon J. Patterson (University of Iowa). Other Committee members were Paul W. Jungnickel, Chair (Auburn University), Lisa A.
    [Show full text]
  • International Standards for the Treatment of Drug Use Disorders
    "*+,-.*--- -!"#$%&-'",()0"ÿ23 45 "6789!"7(@&A($!7,0B"67$!C#+D"%"*+,9779C&B"!7%EE F33"*+,-.*--- -!"#$%&-'",()0" International standards for the treatment of drug use disorders REVISED EDITION INCORPORATING RESULTS OF FIELD-TESTING International standards for the treatment of drug use disorders: revised edition incorporating results of field-testing ISBN 978-92-4-000219-7 (electronic version) ISBN 978-92-4-000220-3 (print version) © World Health Organization and United Nations Office on Drugs and Crime, 2020 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this license, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO or UNODC endorses any specific organization, products or services. The unauthorized use of the WHO or UNODC names or logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO) or the United Nations Office on Drugs and Crime (UNODC). Neither WHO nor UNODC are responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the license shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.
    [Show full text]
  • Running Head: PHARMACOLOGICAL TREATMENT for METHAMPHETAMINE
    Running head: PHARMACOLOGICAL TREATMENT FOR METHAMPHETAMINE PHARMACOLOGICAL TREATMENT FOR METHAMPHETAMINE DEPENDENCE By BRINN CULVER A project submitted in partial fulfillment of the requirements for the degree of MASTER OF NURSING WASHINGTON STATE UNIVERSITY Department of Nursing APRIL 2014 PHARMACOLOGICAL TREATMENT FOR METHAMPHETAMINE ii To the Faculty of Washington State University: The members of the Committee appointed to examine the dissertation/thesis of BRINN CULVER find it satisfactory and recommend that it be accepted. Julie DeWitt-Kamada, DNP, ARNP, PMHNP Chair Anne Mason, DNP, ARNP, PMHNP Dawn Rondeau, DNP, ACNP, FNP PHARMACOLOGICAL TREATMENT FOR METHAMPHETAMINE iii PHARMACOLOGICAL TREATMENT FOR METHAMPHETAMINE DEPENDENCE Abstract By Brinn Culver Washington State University April 2014 Chair: Julie DeWitt-Kamada Methamphetamine (MA) is a highly addictive drug whose abuse causes widespread global consequences. The negative impact of MA use on individuals and communities warrants its consideration as a public health concern. MA has a complicated pharmacological action, and chronic use results in neurological dysfunction, including deficits in dopamine. Changes in dopaminergic function make treatment of MA dependence especially challenging, and the mainstay treatment of psychotherapy is insufficient in addressing dopamine deficit. Pharmacological treatments are being explored, but no medication has attained Federal Drug Administration approval, as it requires proof of achieving abstinence. From a harm reduction standpoint, several
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Programme & Abstracts
    The 57th Annual Meeting of the International Association of Forensic Toxicologists. 2nd - 6th September 2019 BIRMINGHAM, UK The ICC Birmingham Broad Street, Birmingham B1 2EA Programme & Abstracts 1 Thank You to our Sponsors PlatinUm Gold Silver Bronze 2 3 Contents Welcome message 5 Committees 6 General information 7 iCC maps 8 exhibitors list 10 Exhibition Hall 11 Social Programme 14 opening Ceremony 15 Schedule 16 Oral Programme MONDAY 2 September 19 TUESDAY 3 September 21 THURSDAY 5 September 28 FRIDAY 6 September 35 vendor Seminars 42 Posters 46 oral abstracts 82 Poster abstracts 178 4 Welcome Message It is our great pleasure to welcome you to TIAFT Gala Dinner at the ICC on Friday evening. On the accompanying pages you will see a strong the UK for the 57th Annual Meeting of scientific agenda relevant to modern toxicology and we The International Association of Forensic thank all those who submitted an abstract and the Toxicologists Scientific Committees for making the scientific programme (TIAFT) between 2nd and 6th a success. Starting with a large Young Scientists September 2019. Symposium and Dr Yoo Memorial plenary lecture by Prof Tony Moffat on Monday, there are oral session topics in It has been decades since the Annual Meeting has taken Clinical & Post-Mortem Toxicology on Tuesday, place in the country where TIAFT was founded over 50 years Human Behaviour Toxicology & Drug-Facilitated Crime on ago. The meeting is supported by LTG (London Toxicology Thursday and Toxicology in Sport, New Innovations and Group) and the UKIAFT (UK & Ireland Association of Novel Research & Employment/Occupational Toxicology Forensic Toxicologists) and we thank all our exhibitors and on Friday.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Recommended Methods for the Identification and Analysis of Fentanyl and Its Analogues in Biological Specimens
    Recommended methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2017 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/53 Original language: English © United Nations, November 2017. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr. Barry Logan, Center for Forensic Science Research and Education, at the Fredric Rieders Family Founda- tion and NMS Labs, United States; Amanda L.A.
    [Show full text]
  • Understanding and Challenging the Drugs: Chemistry and Toxicology
    UNDERSTANDING AND CHALLENGING THE DRUGS: CHEMISTRY AND TOXICOLOGY Presenter: • Dr. Jasmine Drake, Graduate Program Director and Assistant Professor, Administration of Justice Department, Barbara Jordan-Mickey Leland School of Public Affairs, Texas Southern University NACDL Training Defending Drug Overdose Homicides in Pennsylvania Penn State Harrisburg, Middletown, PA November 6th, 2019 11:30- 12:45 p.m. Understanding & Challenging the Drugs: Chemistry & Toxicology Dr. Jasmine Drake, Forensic Science Learning Laboratory, Texas Southern University I. Opioid Drug Classifications A. Types of Opioids B. Classic vs. Synthetic C. Toxicology of Opioids 1) How opioids interact with the body 2) Addiction (psychological vs. physiological II. New Classes of Drugs A. Emerging Threats B. Potency III. National Trends in Opioid Overdose Deaths in the U.S. A. Based on State B. Ethnicity C. Drug-Type (prescription vs. fentanyl vs. heroin) IV. Trends of Opioid Overdose Deaths in Philadelphia A. Based on Ethnicity B. Drug Type (prescription vs. fentanyl vs. heroin) V. Legal Considerations to the Opioid Epidemic A. Punitive Measures vs. Rehabilitative Treatment B. Progressive Jurisdictions Nationwide C. New Legal Measures in Philadelphia VI. Toxicology Reports A. What’s in the report? B. Key Aspects of the Tox Report C. Terminology D. Evaluating and Interpreting the data? E. Questions and considerations. VII. Conclusion and Discussion A. Case Specific Examples B. Sample Toxicology Reports The Opioid Epidemic: What labs have to do with it? Ewa King, Ph.D. Associate Director of Health RIDOH State Health Laboratories Analysis. Answers. Action. www.aphl.org Overview • Overdose trends • Opioids and their effects • Analytical testing approaches • Toxicology laboratories Analysis. Answers. Action.
    [Show full text]
  • Grayanotoxin Poisoning in Humans from Honey Consumption HELENA COLOMA DÍEZ AUTONOMOUS UNIVERSITY of BARCELONA
    Grayanotoxin Poisoning in Humans from Honey Consumption HELENA COLOMA DÍEZ AUTONOMOUS UNIVERSITY OF BARCELONA Objectives Structure, Types and Isolation of GTX The main objective of this bibliographic research is compiling and announcing information Grayanotoxins are non-volatile diterpenes, a about grayanotoxin-containing honey and the toxic effects derived from its ingestion. This polyhidroxylated cyclic hydrocarbon with a 5/7/6/5 ring substance is believed to have medicinal properties, and the current increment of use of structure that does not contain nitrogen, as seen on figure 2. There are 25 known isoforms of grayanotoxins, natural products as dietetic complements with this finality may cause a rising in the number GTX-I and GTX-III being the most common and of intoxication cases. So it is important learning to recognise the clinical signs it causes and abundant ones, followed by GTX-II. their treatment, apart from finding out if it may have medicinal applications. TheGTXcanbeisolatedbytypicalextraction procedures for naturally occurring terpenes, such as paper electrophoresis, thin-layer chromatography (TLC), and gas chromatography (GC). They require derivatization before GC analysis due to the Introduction compound’s instability on heating and having low vapor pressure. Other identification techniques are based on The poisoning caused by grayanotoxin-containing honey, called “mad honey”, is known from infrared (IR), nuclear magnetic resonance (NMR), and antiquity. This toxic honey has been used for different purposes, such as biological weapon mass spectrometry (MS). or therapeutical product. Figure 2. Structure formulas (left pannel) and 3D The origin of this toxin relays in some plants of the Rhododendron genus, widespread all representations (right pannel) of GTX-I, II and III.
    [Show full text]
  • Learning Objectives
    2/26/2019 To help ensure the integrity of competition for Dirty Dozen: High Risk athletes, sports organizations and fans Sport Supplement worldwide. Ingredients Lara Gray, MS, RD, CSSD Senior Director of Education, Board Certified Sports Dietitian 1 Welcome! Learning Objectives Things to note: At the end of the presentation, attendees will 1. It is required by the BOC for Certified Athletic Trainers that you are actively be better able to: present in the live event AND complete the post-webinar survey in order to • Identify dietary ingredients that pose a threat to drug tested athletes. receive your CEU certificate. • Explain how high risk dietary ingredients are being used in sports 2. CEU Statements of Credit (if applicable) supplements. will be emailed to attendees no later than Friday, March 1st. • Analyze sports supplements for high risk dietary ingredients. 3. Please use the “Questions” box in GoToWebinar. Questions will be reviewed by the moderator and answered at the Drug Free Sport International (BOC AP# P8729) is approved by the Board of Certification, Inc. to end. provide continuing education to Athletic Trainers. This program is eligible for a maximum of 1 Category A hour/CEU. ATs should claim only those hours actually spent in the educational program. 4. Download today’s handouts from the “Handouts” tab. 1 2/26/2019 Today: An In-Depth Look 40% - 100% ATHLETES USE SUPPLEMENTS • Type of sport • Level of competition • Definition of supplements Garthe, Ina, and Ronald J. Maughan. "Athletes and Supplements: Prevalence and Perspectives." International journal of sport nutrition and exercise metabolism 28.2 (2018): 126‐138.
    [Show full text]
  • Forensic Science
    Anal. Chem. 1999, 71, 235R-255R Forensic Science T. A. Brettell* Forensic Science Bureau, New Jersey State Police, Box 7068, West Trenton, New Jersey 08625 K. Inman California Department of Justice DNA Laboratory, 626 Bancroft Way, Berkeley, California 94710 N. Rudin² 1563 Solano Ave. #506, Berkeley, California 94707 R. Saferstein³ Box 1334, Mount Laurel, New Jersey 08054 Review Contents Canadian Society of Forensic Science, Journal of Forensic Identifica- Drugs and Poisons 235R tion, Forensic Science Review, Analytical Toxicology, Electrophoresis, Ethanol and Volatiles 235R and BioTechniques, as well as Chemical Abstracts Selects: Forensic Cannabinoids 236R Chemistry. Our survey encompasses the period from January 1997 Morphine and Related Narcotics 237R through December 1998. Because of the normal delays in the Cocaine 237R abstraction of journal articles by Chemical Abstracts, some work Amphetamines 238R covering this period will inadvertently be omitted. Hopefully these Barbiturates 239R references will be included in the next biennial review. Benzodiazepines 239R The format selected for this survey divides coverage into three Miscellaneous Drugs and Poisons 239R distinct areas: drug and poisons, forensic DNA analysis, and trace General Procedures 241R Forensic DNA Analysis 242R evidence. Within the scope of each of the areas, articles have been DNA Extraction and Quantitation 242R selected to describe current forensic science practices in analytical Restriction Fragment Length Polymorphisms 242R chemistry and to outline relevant forensic science research Amplified Fragment Length Polymorphisms 242R interests. To keep our discussion concise and meaningful, we have Short Tandem Repeats 242R limited our survey to drugs regulated under the United States Gender Identification 243R Controlled Substances Act, ethanol, and common poisons.
    [Show full text]